Sucampo Seeks To Terminate Amitiza Marketing Agreement With Takeda
This article was originally published in The Pink Sheet Daily
Executive Summary
Sucampo Pharmaceuticals requests arbitration to end its partnership with Takeda, claiming the company has failed to maximize sales of the constipation drug Amitiza.
You may also be interested in...
Amitiza Hits Mark In Confirmatory Opioid-Induced Bowel Dysfunction Study
Sucampo/Takeda’s constipation treatment Amitiza meets primary endpoint in Phase III study of OBD, with a clean safety profile. Sucampo now sets its sights on a supplemental NDA for a third indication.
Sucampo Releases Positive Phase III Data For Amitiza In Japan
TOKYO - Sucampo's chronic idiopathic constipation treatment Amitiza (lubiprostone) may soon have a chance at a second life in a new market after the company announced positive results of a pivotal Phase III trial in Japanese patients
Sucampo Releases Positive Phase III Data For Amitiza In Japan
TOKYO - Sucampo's chronic idiopathic constipation treatment Amitiza (lubiprostone) may soon have a chance at a second life in a new market after the company announced positive results of a pivotal Phase III trial in Japanese patients